Chen Weiming,Bai Jianxi,Zhang Bing,et al.Establishment and validation of a survival prediction model for children with neuroblastoma[J].Journal of Clinical Pediatric Surgery,2025,(03):243-249.[doi:10.3760/cma.j.cn101785-202207009-008]
神经母细胞瘤患儿生存预测模型的构建和验证
- Title:
- Establishment and validation of a survival prediction model for children with neuroblastoma
- Keywords:
- Neuroblastoma; Nomogram; Prognosis; Surgical Procedures; Operative; Child
- 摘要:
- 目的 构建用于评估神经母细胞瘤患儿生存预后的临床预测模型。方法 从美国国立癌症研究所的“监测、流行病学和最终结果”(Surveillance,Epidemiology,and End Results,SEER)数据库中收集2000—2019年间公开发布的神经母细胞瘤患儿临床资料,将筛选后的数据按2∶1的比例随机划分为训练集和验证集。采用单因素和多因素Cox比例风险回归模型确定预后相关因素,构建神经母细胞瘤预后预测模型并绘制列线图。采用一致性指数(C指数)、受试者操作特征(receiver operating characteristic,ROC)曲线下面积(area under curve,AUC)和校准曲线评估列线图的辨别和校准能力,采用决策曲线分析(decision curve analysis,DCA)评价列线图的临床实用性。结果 多因素Cox回归分析结果显示:年龄1~5岁(HR=3.595,95%CI:2.122~6.091)或≥5岁(HR=4.556,95%CI:2.566~8.091)、肿瘤长径≥7.5 cm (HR=1.934,95%CI:1.347~2.777)、肿瘤位于肾上腺和腹膜后(HR=1.520,95%CI:1.029~2.247)、肿瘤转移(HR=5.263,95%CI:2.146~12.907)和未接受手术治疗(HR=1.866,95%CI:1.225~2.833)为神经母细胞瘤患儿预后不良的独立危险因素。将上述变量纳入预测模型并绘制列线图,进行1、3、5年的总生存率预测。预测模型在训练集和验证集中的C指数分别为0.803和0.785,训练集中ROC曲线在1、3、5年的总生存率预测AUC值分别为0.782、0.829、0.842,验证集中分别为0.748、0.807、0.855。DCA曲线表明,列线图的预测概率阈值在0.1~0.6之间时,使用列线图预测神经母细胞瘤患儿的预后更准确。结论 年龄≥1岁、肿瘤长径≥7.5 cm、肿瘤原发于肾上腺和腹膜后、存在远处转移和未接受手术治疗是神经母细胞瘤患儿预后不良的独立危险因素,据此构建的预测模型能较为准确地预测神经母细胞瘤患儿预后,为临床决策提供参考。
- Abstract:
- Objective To establish and validate a clinical prediction model assessing the survival of children with neuroblastoma (NB). Methods The relevant clinical data were collected from NB children between 2000 and 2019 from the database of Surveillance,Epidemiology and End Results (SEER).The primary cohort was randomized into two sets of training (n=987) and validation (n=493).The prognostic effects of variables were examined with a Cox proportional hazard model.Nomograms were established for estimating 1/3/5-year overall survival (OS) based upon Cox regression model.Concordance index (C-index),area under time-dependent receiver operating characteristics curve (AUC-ROC),calibration plotting and decision-curve analysis (DCA) were utilized for evaluating the model. Results The results of the multivariate Cox regression analysis indicated that 1-5 years (HR=3.595,95%CI:2.122-6.091) or ≥5 years (HR=4.556,95%CI:2.566-8.091),tumour length ≥7.5 cm (HR=1.934,95%CI:1.347-2.777),tumour located in the adrenal and retroperitoneal (HR=1.520,95%CI:1.029-2.247),tumour metastasis (HR=5.263,95%CI:2.146-12.907),and not receiving surgical treatment (HR=1.866,95%CI:1.225-2.833) were identified as independent risk factors for poor prognosis in children with neuroblastoma.A nomogram was constructed based on the aforementioned independent prognostic factors for the purpose of overall survival prediction at 1/3/5-year in children with neuroblastoma.C-index of prediction model in training and validation sets were 0.803 and 0.785 respectively.AUC of ROC curves in training set at 1/3/5-year overall survival were 0.782,0.829 and 0.842 respectively.Validation set revealed that AUC of ROC curve of 1/3/5-year overall survival were 0.748,0.807 and 0.855 respectively.DCA indicated that using the nomogram for predicting the prognosis of NB children was more beneficial at a prediction probability threshold of (0.1-0.6). Conclusions Nomogram is a reliable and powerful tool for distinguishing and predicting the survival of NB children,thus assisting clinicians in making clinical decisions.
参考文献/References:
[1] Ponzoni M,Bachetti T,Corrias MV,et al.Recent advances in the developmental origin of neuroblastoma:an overview[J].J Exp Clin Cancer Res,2022,41(1):92.DOI:10.1186/s13046-022-02281-w.
[2] Liu ZH,Thiele CJ.Unraveling the enigmatic origin of neuroblastoma[J].Cancer Cell,2020,38(5):618-620.DOI:10.1016/j.ccell.2020.10.016.
[3] 王鹏程,董瑞.神经母细胞瘤4S期预后不良相关因素的研究进展[J].临床小儿外科杂志,2022,21(4):394-398.DOI:10.3760/cma.j.cn101785-202108053-019. Wang PC,Dong R.Research advances on poor prognostic factors of children with stage 4S neuroblastoma[J].DOI:10.3760/cma.j.cn101785-202108053-019.
[4] Johnsen JI,Dyberg C,Wickstr?m M.Neuroblastoma-a neural crest derived embryonal malignancy[J].Front Mol Neurosci,2019,12:9.DOI:10.3389/fnmol.2019.00009.
[5] Iasonos A,Schrag D,Raj GV,et al.How to build and interpret a nomogram for cancer prognosis[J].J Clin Oncol,2008,26(8):1364-1370.DOI:10.1200/JCO.2007.12.9791.
[6] Surveillance,Epidemiology,and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database:incidence-SEER research plus data,18 registries,Nov 2020 sub (2000-2018)-linked to county attributes-total U.S.,1969-2019 counties,National Cancer Institute,DCCPS,Surveillance Research Program,released April 2021,based on the November 2020 submission[Z].
[7] 刘书霞,张磊,石远凯,等.非转移性结直肠癌患者术后预后影响因素分析及列线图预测模型的构建[J].中华肿瘤杂志,2022,44(2):167-172.DOI:10.3760/cma.j.cn112152-20200321-00244. Liu SX,Zhang L,Shi YK,et al.Analysis of related factors of prognosis after surgical treatment of patients with non-metastatic colorectal cancer and construction of a normagram prediction model[J].Chin J Oncol,2022,44(2):167-172.DOI:10.3760/cma.j.cn112152-20200321-00244.
[8] Wang RJ,Dai WX,Gong J,et al.Development of a novel combined nomogram model integrating deep learning-pathomics,radiomics and immunoscore to predict postoperative outcome of colorectal cancer lung metastasis patients[J].J Hematol Oncol,2022,15(1):11.DOI:10.1186/s13045-022-01225-3.
[9] Huang X,Luo Z,Liang W,et al.Survival nomogram for young breast cancer patients based on the SEER database and an external validation cohort[J].Ann Surg Oncol,2022,29(9):5772-5781.DOI:10.1245/s10434-022-11911-8.
[10] Ohira M,Nakamura Y,Takimoto T,et al.Retrospective analysis of INRG clinical and genomic factors for 605 neuroblastomas in Japan:a report from the Japan Children’s Cancer Group Neuroblastoma Committee (JCCG-JNBSG)[J].Biomolecules,2021,12(1):18.DOI:10.3390/biom12010018.
[14] Pastor ER,Mousa SA.Current management of neuroblastoma and future direction[J].Crit Rev Oncol Hematol,2019,138:38-43.DOI:10.1016/j.critrevonc.2019.03.013.
[15] Coughlan D,Gianferante M,Lynch CF,et al.Treatment and survival of childhood neuroblastoma:evidence from a population-based study in the United States[J].Pediatr Hematol Oncol,2017,34(5):320-330.DOI:10.1080/08880018.2017.1373315.
[11] 中国抗癌协会小儿肿瘤专业委员会,中华医学会小儿外科学分会肿瘤外科学组.儿童神经母细胞瘤诊疗专家共识[J].中华小儿外科杂志,2015,36(1):3-7.DOI:10.3760/cma.j.issn.0253-3006.2015.01.002. Professional Committee of Pediatric Oncology,China Anti-Cancer Association,Group of Oncology Surgery,Branch of Pediatric Surgery,Chinese Medical Association.Expert consensus on diagnosing and treating neuroblastoma in children[J].Chin J Pediatr Surg,2015,36(1):3-7.DOI:10.3760/cma.j.issn.0253-3006.2015.01.002.
[12] Ryan AL,Akinkuotu A,Pierro A,et al.The role of surgery in high-risk neuroblastoma[J].J Pediatr Hematol Oncol,2020,42(1):1-7.DOI:10.1097/mph.0000000000001607.
[13] Ahmed G,Fawzy M,Elmenawi S,et al.Role of surgery in localized initially unresectable neuroblastoma[J].J Pediatr Urol,2018,14(3):231-236.DOI:10.1016/j.jpurol.2018.03.008.
[14] Holmes K,P?tschger U,Pearson ADJ,et al.Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma:a report from the HR-NBL1/SIOPEN study[J].J Clin Oncol,2020,38(25):2902-2915.DOI:10.1200/jco.19.03117.
[15] Bianco FJ Jr.Nomograms and medicine[J].Eur Urol,2006,50(5):884-886.DOI:10.1016/j.eururo.2006.07.043.
相似文献/References:
[1]郭春宝,王珊,金先庆,等.Cochrane系统评价方法对神经母细胞瘤分子与生物标记物的Meta分析[J].临床小儿外科杂志,2008,7(01):2.
[2]未德成,王忠荣,张燕敏,等.脂氧合酶抑制剂NDGA对人神经母细胞瘤SK-N-SH细胞生物学特性的影响[J].临床小儿外科杂志,2008,7(01):3.
[3]陈新让,王家祥,余捷凯,等.基于支持向量机神经母细胞瘤血清蛋白质标记物的检测及临床应用[J].临床小儿外科杂志,2008,7(02):12.
[4]罗远建,金科,甘青,等.儿童神经母细胞瘤的影像学表现[J].临床小儿外科杂志,2007,6(02):22.
[5]李昆昆 金先庆 牟廷刚 陈建飞 赵利华 丁雄辉 孙艳辉 王士奇. ATRA耐药基因HA117相关蛋白在四种恶性肿瘤的表达及临床意义[J].临床小儿外科杂志,2011,10(04):250.
[J].Journal of Clinical Pediatric Surgery,2011,10(03):250.
[6]沙永亮 吴晔明. 化疗及非化疗组神经母细胞瘤干细胞标志物的表达及意义[J].临床小儿外科杂志,2011,10(04):254.
[J].Journal of Clinical Pediatric Surgery,2011,10(03):254.
[7]刘涛 韩英 祝秀丹 王焕民 秦红 邹焱. Wnt—5a基因在神经母细胞瘤中的表达及意义[J].临床小儿外科杂志,2011,10(05):333.
[J].Journal of Clinical Pediatric Surgery,2011,10(03):333.
[8]顾 涛 鹿洪亭 董 蒨.Kai1/CD82表达水平与神经母细胞瘤转移的关系探讨[J].临床小儿外科杂志,2013,12(02):100.[doi:10.3969/j.issn.1671— 6353.2013.02.007]
GU Tao,LU Hong-ting,DONG Qian.The relationship between Kai1/CD82 expression and metastasis of neuroblastoma[J].Journal of Clinical Pediatric Surgery,2013,12(03):100.[doi:10.3969/j.issn.1671— 6353.2013.02.007]
[9]邢莉莉,吴晔明,张弛.熊果酸对神经母细胞瘤细胞增殖凋亡及 MYCN表达的影响[J].临床小儿外科杂志,2013,12(03):196.[doi:10.3969/j.issn.1671—6353.2013.03.010]
XING Li li,WU Ye ming,ZHANG Chi..Ursolic acid effects proliferation、apoptosis and MYCN expression of neuroblastoma cell[J].Journal of Clinical Pediatric Surgery,2013,12(03):196.[doi:10.3969/j.issn.1671—6353.2013.03.010]
[10]张雁冰 刘朝阳 卢其 周小渔. RNA干扰对神经母细胞瘤细胞VEGFA的ｍRNA表达的影响[J].临床小儿外科杂志,2013,12(06):471.
备注/Memo
收稿日期:2022-7-6。
基金项目:福建省自然科学基金(2023J011300);福建医科大学启航基金(2021QH1168)
通讯作者:方一凡,Email:fyf0599@163.com